Difference between revisions of "Crizotinib (Xalkori)"
(updated content) |
m (Text replace - "Category:Tyrosine kinase inhibitors" to "Category:Kinase inhibitors") |
||
| Line 19: | Line 19: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category: | + | [[Category:Kinase inhibitors]] |
[[Category:ALK inhibitors]] | [[Category:ALK inhibitors]] | ||
Revision as of 05:56, 30 May 2013
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK), c-MET and subsequent expression of Hepatocyte Growth Factor Receptor (HGFR), and Recepteur d’Origine Nantais (RON). Inhibits activity of fusion proteins involving ALK, such as EML4-ALK and NPM-ALK.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Crizotinib (Xalkori) package insert pages 15-18[1]
- Crizotinib (Xalkori) patient drug information (Chemocare)[3]
- Crizotinib (Xalkori) patient drug information (UpToDate)[4]